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Background
The NIHR HTA programme was established in 1993
with the aim of being ‘needs-led’. This was achieved
through commissioning trials to address questions speci-
fied by the programme rather than by applicants. At the
time this was an unusual funding model and the pro-
gramme has developed experience that is now globally
significant.
There is dissatisfaction worldwide with the focus of
much existing clinical research (the arrival in the USA
of Comparative Effectiveness Research is one attempt to
address this) and many trials focus on outcomes that
are of little relevance to patients [1]. However, apart
from early work reviewing the sources of topics sug-
gested to the HTA programme [2], there has been no
systematic attempt to review the programme’s success
in being needs-led.
Objectives
The establishment of a database of metadata for HTA
trials allowed us to examine the experience from a long
series of published HTA trials. We therefore set out to
review how far trials funded by the NIHR HTA pro-
gramme were indeed needs-led by looking at:
• The source of the original suggestion
• The priority given by the programme to the research
• The patient-relevance of the primary outcome
Methods
The study used a variety of methods to assess the extent
to which HTA trials published up to March 2011 were
needs-led (n=112). The sources of topic identification
and the prioritisation methods were examined over a 10
year period. The type of primary outcome measure
reported during the commissioning stage, research pro-
tocol and HTA monograph were assessed using Gandhi
et al. (2008) [1] classification list.
Results
The source of the original suggestion: 77/112 trials (69%)
addressed questions that came out of the widespread
consultation, a mix of postal and online questionnaires
of managers, clinicians and patient and professional
groups. Majority of the remaining trials were from sys-
tematic reviews (22%, 25/112).
The priority given by the programme to the research:
58/84 had been recommended as ‘must commission’
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Table 1 Summary data
Description No (%)
Sources used to identify research suggestions:
Widespread consultation 77 (68.8)
Systematic review / DARE review 25 (22.3)
Horizon Scanning Centre 3 (2.7)
Reconsidered / recycled topics 5 (4.5)
No data available 2 (1.8)
Priority given by the programme to the research:
(up to and including publication date 1999)
Recommended for commissioning – must commission 58 (51.8)
Recommended for commissioning 22 (19.6)
Category unknown (FT and NSCAG) 4 (3.6)
(Post 1999)
Commissioning requested by PSG 27 (24.1)
Direct commissioning in priority area 1 (0.9)
Actual type of primary outcome reported in the monograph:
Patient important (including those with additional outcomes) 84 (75.0)
Surrogate 7 (6.3)
Physiological / laboratory 1 (0.9)
Other 18 (16.1)
No information available / unable to judge primary outcome 2 (1.8)
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priorities by the HTA programme, meaning that they
would be advertised and if that failed to result in fund-
ing, further work would be done to ensure that they
were taken forward.
The patient-relevance of the primary outcome: Three
quarters of trials addressed patient relevant outcomes
(75%, 84/112). This compares with 46% and 45% in pre-
vious studies [1], [3].
Conclusions
These analyses suggest that the first 112 published HTA
trials can indeed claim to be meeting the information
needs of the NHS. Further work is required to compare
these results with elsewhere and to develop more robust
measures for the future.
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